Abbott Medical Devices
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Abbott Medical Devices sits in the top decile of US sponsors by registered trial count (#127 of 15,742 sponsors by registered trial count).
Abbott Medical Devices: 261 sponsored US clinical trials, 23 recruiting.
Abbott Medical Devices sponsors 261 registered US clinical trials on ClinicalTrials.gov, 23 of them currently recruiting, and 186 completed. 17 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Heart Failure, with 15 trials.
Top-decile sponsor footprint
Abbott Medical Devices ranks in the top decile of sponsors by registered trial count (#127 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
186 of 211 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
261 total, page 2 of 6
AVEIR Remote Care System Non-Significant Risk Study
NCT06542133
VOLT-AF IDE Clinical Study
NCT06223789
LBBAP Data Collection Registry
NCT05887323
Validation of CardioMEMS HF System Cardiac Output Algorithm IDE
NCT05428384
Patient Preferences for Leadless Pacemakers
NCT05327101
ECGi of SyncAV With MultiPoint Pacing
NCT06444386
Perclose Multi-Access Duplex Ultrasound (DUS) Study
NCT04904809
Real-World Outcomes Study on Subjects Treated With Radiofrequency Ablation
NCT04873817
Spinal Cord Stimulation Trial to Permanent Prediction
NCT05659836
CentriMag Failure-to-Wean Post Approval Study
NCT04464785
Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical SWIFT HM3 PMS
NCT04548128
Spinal Cord Stimulation vs. Medical Management for Low Back Pain (DISTINCT)
NCT04479787
The ARIES HeartMate 3 Pump IDE Study
NCT04069156
TactiFlex Paroxysmal Atrial Fibrillation IDE Trial
NCT04356040
FUnctional diagnoSIs of corONary Stenosis (FUSION)
NCT04356027
Abbott Next Generation Drug Eluting Stent 48mm Study
NCT04282148
JETi Lower Extremity Arterial Thrombosis
NCT04370691
Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool
NCT03794661
MOMENTUM 3 Pivotal Cohort Extended Follow-up PAS
NCT03982979
Radial accEss for nAvigation to Your CHosen Lesion for Peripheral Vascular Intervention: REACH PVI
NCT03943160
LSI (Lesion Index) Workflow Observational Study
NCT03906461
PROLONG Prospective, Multi-center, Open-label, Post-market Study
NCT03908476
A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
NCT03884231
Mapping and Pacing of the His Bundle for Heart Failure Patients With Left Bundle Branch Block
NCT03803995
XIENCE 28 USA Study
NCT03815175
Physiologic Pacing Registry
NCT03719040
Feasibility Study of the Tendyne Mitral Valve System in Mitral Annular Calcification
NCT03539458
The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study
NCT03165526
Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
NCT03650556
HBP Device EGM Data Collection
NCT03564860
Intraoperative Investigation of a Directional Lead and Local Field Potentials for the Optimization of Stimulation Efficacy
NCT03630302
FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study
NCT03490201
ILUMIEN IV: OPTIMAL Percutaneous Coronary Intervention (PCI)
NCT03507777
The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices
NCT03502811
Hemodynamic-GUIDEd Management of Heart Failure
NCT03387813
TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation
NCT03354663
BurstDR™ micrOdosing stimuLation in De-novo Patients
NCT03350256
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional MR
NCT07227675
Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial
NCT03277378
EnSite Precision Observational Study
NCT03260244
Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™
NCT03247829
TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR
NCT03227757
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
NCT03218787
SJM Brady MRI Post Approval Study
NCT03170583
AMPLATZER Duct Occluder II Additional Sizes
NCT03055858
IPG Replacement Study (PREFERENCE-H)
NCT02963259
Trifecta™ GT Post Market Clinical Follow-up
NCT03016169
Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator
NCT03082261
Clinical Evaluation of the Infinity Deep Brain Stimulation System
NCT02989610
The Application of Negative Atrioventricular Hysteresis in Cardiac Resynchronization Therapy
NCT02903940
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 11 |
| Phase 4 | 6 |
Therapeutic Areas
Where Abbott Medical Devices enrollment is open (later-stage tilt)
23 recruiting of 261 indexed (9% open); 186 completed (71%).
Phase mix: 17 late (III/IV) vs 5 early (I/II) (later-stage heavy).
Top condition: Heart Failure (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abbott Medical Devices: open-pipeline peers nationwide
Peers matched on 261 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Abbott Medical Devices sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 261 trials (± recruiting share)
- Pennington Biomedical Research Center · 258 trials · 13% recruiting
- Novartis · 265 trials · 0% recruiting
- University of Texas at Austin · 257 trials · 23% recruiting
- Boston Medical Center · 253 trials · 11% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Grifols Therapeutics · 9% recruiting · 34 trials
- Butler Hospital · 9% recruiting · 103 trials
- AMAG Pharmaceuticals · 9% recruiting · 23 trials
- Iowa State University · 9% recruiting · 23 trials
Related
What to do with this Abbott Medical Devices page
261 registered trials is a research-attention snapshot, not an endorsement of Abbott Medical Devices or any single study.
- 23 of Abbott Medical Devices's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Heart Failure is the condition Abbott Medical Devices studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Heart Failure trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abbott Medical Devices pipeline card: 261 registered trials from official public datasets.Report a data error.